Adagene Inc. ADAG announced that the FDA has granted Fast Track designation to its lead clinical-stage immuno-oncology ...
Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal ...
Chemotherapy drugs that target cancer cells without damaging normal cells remain one of the key goals of precision medicine ...
1. Brenner A, Youssef M, Kumthekar P, et al. Rhenium (¹⁸⁶Re) obisbemeda (rhenium nanoliposome, ¹⁸⁶RNL) for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback